Skip to main content
Log in

Adverse Reactions with 3,4-Methylenedioxymethamphetamine (MDMA; ‘Ecstasy’)

  • Review Article
  • Drug Experience
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

3,4-Methylenedioxymethamphetamine (MDMA; ‘ecstasy’) is an increasingly popular recreational drug in the US, Western Europe and Australia. In animals, including nonhuman primates, MDMA is known to damage brain serotonin (5-hydroxytryptamine; 5-HT) neurons. It is not known whether MDMA damages serotonin neurons in the human brain but there is some indication that it may. Although the large majority of individuals who have used MDMA recreationally do not develop acute complications, as the popularity of MDMA has increased, so have reports of adverse nonpsychiatric and psychiatric consequences associated with use of the drug. Further, since manifestations of MDMA-induced serotonin injury might only become apparent with age, or under periods of stress, it is possible that some individuals with no apparent abnormalities might develop complications over time.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Shulgin AT, Nichols DE. Characterization of three new psychotomimetics. In: Stillman R, Willette R, editors. The psychopharmacology of hallucinogens. New York: Pergamon Press, 1978: 74–83

    Google Scholar 

  2. Greer G. Using MDMA in psychotherapy. Advances 1985; 2(2): 57

    Google Scholar 

  3. Greer G, Strassman RJ. Information on ecstasy [letter]. Am J Psychiatry 1985; 142: 1391

    PubMed  CAS  Google Scholar 

  4. Lawn JC. Schedules of controlled substances; temporary placement of 3,4-methylenedioxymethamphetamine. J Pharm Exp Ther 1987; 240: 1–7

    Google Scholar 

  5. Ricaurte G, Bryan G, Strauss L, et al. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 1985; 229: 986–8

    Article  PubMed  CAS  Google Scholar 

  6. Abbot A, Concar D. A trip into the unknown. New Sci 1992; 29: 30–4

    Google Scholar 

  7. Randall T. (1992) Ecstasy-fueled ‘rave’ parties become dances of death for English youths. JAMA 1992; 268(12): 1505–6

    Article  PubMed  CAS  Google Scholar 

  8. Schmidt CJ. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharm Exp Ther 1987; 240: 1–7

    CAS  Google Scholar 

  9. Commins DL, Vosmer G, Virus R, et al. Biochemical and histological evidence that methylenedioxymethamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 1987; 241: 338–45

    PubMed  CAS  Google Scholar 

  10. O’Hearn EG, Battaglia G, De Souza, et al. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence. J Neurosci 1988: 8: 2788–803

    PubMed  Google Scholar 

  11. Battaglia G, Yeh SY, O’Hearn E, et al. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetinelabelled serotonin uptake sites. J Pharmacol Exp Ther 1987; 242(3): 911–6

    PubMed  CAS  Google Scholar 

  12. Stone DM, Stahl DS, Hanson GL, et al. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine on monoaminergic systems in the rat brain. Eur J Pharmacol 1986; 128: 41–8

    Article  PubMed  CAS  Google Scholar 

  13. Slikker W, Ali SF, Scallet C, et al. Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). Toxicol Appl Pharmacol 1988; 94: 448–57

    Article  PubMed  CAS  Google Scholar 

  14. Slikker Jr W, Holson RR, Ali SF, et al. Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate. Neurotoxicology 1989; 10(3): 529–49

    PubMed  CAS  Google Scholar 

  15. Ricaurte GA, Forno LS, Wilson MA, et al. (+)3,4-methylenedioxymethamphetamine (MDMA) selectively damaged central serotonergic neurons in non human primates. JAMA 1988; 260(1): 51–5

    Article  PubMed  CAS  Google Scholar 

  16. Insel T, Battaglia G, Johannessen J, et al. 3,4-methylenedioxymethamphetamine (‘Ecstasy’) selectively destroys brain serotonin terminals in rhesus monkeys. J Pharm Exp Ther 1989; 249(3): 713–20

    CAS  Google Scholar 

  17. Molliver ME, Berger UV, Mamounas LA, et al. Neurotoxicity of MDMA and related compounds: anatomic studies. Ann NY Acad Sci 1990; 600: 640–64

    Article  Google Scholar 

  18. Wilson MA, Ricaurte GA, Molliver ME. Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to MDMA. Neuroscience 1989; 28: 121–37

    Article  PubMed  CAS  Google Scholar 

  19. Ricaurte GA, Katz JL, Martello MB. Lasting effects of (±)3,4-methylenedioxymethamphetamine on central serotonergic neurons in non-human primates. J Pharmacol Exp Ther 1992; 261(2): 616–22

    PubMed  CAS  Google Scholar 

  20. Ricaurte GA, DeLanney LE, Irwin I, et al. Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res 1988; 446: 165–8

    Article  PubMed  CAS  Google Scholar 

  21. McCann UD, Ricaurte GA. Strategies for detecting partial monoamine depletions in humans. Natl Inst Drug Abuse Res Monogr Ser 1993; 136: 35–52

    Google Scholar 

  22. McCann UD, Ridenour A, Shaham Y, et al. Brain serotonergic neurotoxicity after MDMA (‘ecstasy’): a controlled study in humans. Neuropsychopharmacology 1994; 10: 129–38

    PubMed  CAS  Google Scholar 

  23. Seymour RB. MDMA. San Francisco: Haight Ashbury Publications, 1986

    Google Scholar 

  24. Downing J. The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs 1986; 18: 335–40

    Article  PubMed  CAS  Google Scholar 

  25. Greer G, Tolbert P. Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 1986; 18: 319–27

    Article  PubMed  CAS  Google Scholar 

  26. Peroutka SJ, Newman H, Harris H. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1988; 1(4): 273–7

    PubMed  CAS  Google Scholar 

  27. Leister MB, Grob CS, Bravo GL, et al. Phenomenology and sequelae of 3,4-Methylenedioxymethamphetamine use. J Nerv Ment Dis 1992; 180: 345–52

    Article  Google Scholar 

  28. Solowij N, Hall W, Lee N. Recreational MDMA use in Sydney: a profile of ‘ecstasy’ users and their experiences with the drug. Br J Addict 1992; 87: 1161–72

    Article  PubMed  CAS  Google Scholar 

  29. O’Neill D, Dart J. Methylenedioxymethamphetamine (‘Ecstasy’) associated keratopathy. Eye 1993; 7: 805–6

    Article  PubMed  Google Scholar 

  30. Bryden AA, Rothwell PJN, O’Reilly PH. Urinary retention with misuse of ‘Ecstasy’ [letter]. BMJ 1995; 310: 504

    Article  PubMed  CAS  Google Scholar 

  31. Levine AJ, Drew S, Rees GM. ‘Ecstasy’ induced pneumomediastinum. J R Soc Med 1993: 86: 232–3

    PubMed  CAS  Google Scholar 

  32. Rittoo D, Rittoo DB, Rittoo D. Misuse of ecstasy [letter]. BMJ 1992: 305: 309

    Article  PubMed  CAS  Google Scholar 

  33. Satchell SC, Connaughton M. Inappropriate hormone secretion and extreme rises in serum creatinine kinase following MDMA ingestion. BMJ 1994; 51(9): 495

    CAS  Google Scholar 

  34. Maxwell DL, Polkey MI, Henry JA. Hyponatraemia and catatonic stupor after taking ‘ecstasy’. BMJ 1993; 27: 1399

    Article  Google Scholar 

  35. Russell ARB, Schwartz RH, Dawling S. Accidental ingestion of ‘ecstasy’ (3,4-methylenedioxymethamphetamine). Arch Dis Child 1992; 67: 1114–5

    Article  Google Scholar 

  36. Dowling GP, McDonough ET, Bost RO. ‘Eve’ and ‘ecstasy’: a report of five deaths associated with the use of MDA and MDMA. JAMA 1987; 257(12): 1615–7

    Article  PubMed  CAS  Google Scholar 

  37. Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine (‘ecstasy’). Lancet 1992; 340: 384–7

    Article  PubMed  CAS  Google Scholar 

  38. Suarez RV, Riemersma R. ‘Ecstasy’ and sudden cardiac death. Am J Forensic Med Path 1988; 9(4): 339–41

    Article  CAS  Google Scholar 

  39. Gledhill JA, Moore DF, Bell D, et al. Subarachnoid hemorrhage associated with MDMA abuse. J Neurol Neurosurg Psych 1993; 56(9): 1036–7

    Article  CAS  Google Scholar 

  40. Hughes JC, McCabe M, Evans RJ. Intracranial haemorrhage associated with ingestion of ‘ecstasy’. Arch Emerg Med 1993; 10: 372–4

    PubMed  CAS  Google Scholar 

  41. Manchanda S, Connolly MJ. Cerebral infarction in association with ecstasy abuse. Postgrad Med J 1993; 69: 874–5

    Article  PubMed  CAS  Google Scholar 

  42. Selmi F, Davies KG, Sharma RR, et al. Intracerebral hemorrhage due to amphetamine abuse: report of two cases with underlying arteriovenous malformations. Br J Neurosurg 1995; 9: 93–6

    Article  PubMed  CAS  Google Scholar 

  43. Harries DP, De Silva R. ‘Ecstasy’ and intracerebral haemorrhage [letter]. Scott Med 1992: 37(5): 476

    Google Scholar 

  44. Hanyu S, Ikeguchi K, Imai H, et al. Cerebral infarction associated with 3,4-methylenedioxymethamphetamine (‘ecstasy’) abuse [letter]. Eur Neurol 1995; 35: 173

    Article  PubMed  CAS  Google Scholar 

  45. Rothwell PM, Grant R. Cerebral venous sinus thrombosis induced by ‘ecstasy’ [letter]. J Neurol Neurosur Psychiatry 1993; 56: 1035–9

    Article  CAS  Google Scholar 

  46. Squier MV, Jalloh S, Hilton-Jones D, et al. Death after ecstasy ingestion: neuropathological findings [letter]. J Neurol Neurosurg Psychiatry 1995; 58: 756

    Article  PubMed  CAS  Google Scholar 

  47. Brown C, Osterloh J. Multiple complications from recreational ingestion of MDMA (‘Ecstasy’). JAMA 1987; 258: 780–1

    Article  PubMed  CAS  Google Scholar 

  48. Chadwick IS, Linsley A, Freemont AJ, et al. Ecstasy, 3–4 methylenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia [letter]. J R Soc Med 1991; 84: 371

    PubMed  CAS  Google Scholar 

  49. Campkin NTA, Davies UM. Another death from ecstasy [letter]. J R Soc Med 1992; 85: 61

    PubMed  CAS  Google Scholar 

  50. Screaton GR, Cairns HS, Sarner M, et al. Hyperpyrexia and rhabdomyolysis after MDMA (‘ecstasy’) abuse [letter]. Lancet 1992; 339(8794): 677–8

    Article  PubMed  CAS  Google Scholar 

  51. Henry J. Ecstasy and the dance of death. BMJ 1992; 305: 5–6

    Article  PubMed  CAS  Google Scholar 

  52. Barrett PJ, Taylor GT. ‘Ecstasy ‘ingestion: a case report of severe complications. J R Soc Med 1993; 86: 233–4

    PubMed  CAS  Google Scholar 

  53. Padkin A. Treating MDMA (‘Ecstasy’) [letter]. Anesthesia 1994; 49(3): 259

    Article  CAS  Google Scholar 

  54. Wake D. Ecstasy overdose: a case study. Intens Crit Care Nurs 1995; 11(1): 6–9

    Article  CAS  Google Scholar 

  55. Walsh T, Carmichael R, Chestnut R. A hyperthermic reaction to ‘ecstasy’ [letter]. Br J Hosp Med 1994; 51(9): 476

    PubMed  CAS  Google Scholar 

  56. Roberts L, Wright H. Survival following intentional massive overdose of ‘ecstasy‘. J Accid Emerg Med 1993; 11: 53–4

    Article  Google Scholar 

  57. Lehmann ED, Thorn CH, Croft DN. Delayed severe rhabdomyolysis after taking ecstasy [letter]. Postgrad Med J 1995; 71: 186–7

    Article  PubMed  CAS  Google Scholar 

  58. Whitaker-Azmitia PM, Aronson TA. ‘Ecstasy’ (MDMA)-induced pain [letter]. Am J Psychiatry 1989; 146(1): 119

    PubMed  CAS  Google Scholar 

  59. McCann UD, Ricaurte GA. MDMA (‘ecstasy’) and panic disorder: induction by a single dose. Biol Psychiatry 1992; 32: 950–3

    Article  PubMed  CAS  Google Scholar 

  60. Pallanti S, Mazzi D. MDMA (ecstasy) precipitation of panic disorder. Biol Psychiatry 1992; 32: 91–5

    Article  PubMed  CAS  Google Scholar 

  61. Cox DE. ‘Rave’ to the grave. Forensic Sci Int 1993; 60: 5–6

    Article  PubMed  CAS  Google Scholar 

  62. Creighton FJ, Black DL, Hyde CE. ‘Ecstasy’ psychosis and flashbacks. Br J Psychiatry 1991; 159: 713–5

    Article  PubMed  CAS  Google Scholar 

  63. Williams H, Meagher D, Galligan P. MDMA (‘ecstasy’): a case of possible drug-induced psychosis. Irish J Med Sci 1993; 162(2): 43–4

    Article  PubMed  CAS  Google Scholar 

  64. Cadier M, Clarke J. Ecstasy and Whizz at a rave resulting in a major burn plus complications. Burn 1993; 19(3): 239–40

    Article  CAS  Google Scholar 

  65. Hooft PJ, Van de Voorde HP. Reckless behaviour related to the use of 3,4 methylenedioxymethamphetamine (ecstasy): apropos of fatal accident during car-surfing. Int J Legal Med 1994; 106: 328–9

    Article  PubMed  CAS  Google Scholar 

  66. Schifano F. Dangerous driving and MDMA (ecstasy) abuse. J Serotonin Res 1995; 1: 53–7

    Google Scholar 

  67. Duxbury AJ. Ecstasy —dental implications [letter]. Br Dent J 1993; 175(1): 38

    Article  PubMed  CAS  Google Scholar 

  68. Smilkstein M, Smolinske SC, Rumack BH. A case MAO inhibitor/ MDMA: agony after ecstasy. Clin Toxicol 1987; 25: 149–59

    Article  CAS  Google Scholar 

  69. Marsh J, Abboudi Z, Gibson F, et al. Aplastic anaemic following exposure to methylenedioxymethamphetamine (‘Ecstasy’). Br J Haematol 1994; 88: 281–5

    Article  PubMed  CAS  Google Scholar 

  70. Shearman JD, Satsangi J, Chapman RWG, et al. Misuse of ecstasy [letter]. BMJ 1992: 305: 309

    Article  PubMed  CAS  Google Scholar 

  71. Ijzermans JNM, Tilanus HW, De Man RA et al. Ecstasy and liver transplantation [letter]. Ann Med Interne (Paris) 1993; 144(8): 568

    CAS  Google Scholar 

  72. Oranje WA, von Pol P, van der Wurff A, et al. XTC-induced hepatitis. Neth J Med 1994; 44: 56–9

    PubMed  CAS  Google Scholar 

  73. Dykhuizen RS, Brunt PW, Atkinson P, et al. Ecstasy induced hepatitis mimicking viral hepatitis. Gut 1995; 36(6): 939–41

    Article  PubMed  CAS  Google Scholar 

  74. Series H, Boeles S, Dorkins E, et al. Psychiatric complications of ‘ecstasy’ use. J Psychopharmacol 1994; 8(1): 60–1

    Article  PubMed  CAS  Google Scholar 

  75. Schifano F, Magni G. MDMA (‘ecstasy’) abuse: psychopathological features and craving for chocolate —a case series. Soc Biol Psychiatry 1994; 36: 763–7

    Article  CAS  Google Scholar 

  76. Mcguire PK, Cope H, Fahy T. Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine (‘ecstasy’). Br J Psychiatry 1994; 165(.3): 391–5

    Article  PubMed  CAS  Google Scholar 

  77. McGuire P, Fahy T. Chronic paranoid psychosis after misuse of MDMA (‘ecstasy’). BMJ 1991; 302: 607

    Article  Google Scholar 

  78. Schifano F. Chronic atypical psychosis associated with MDMA (‘ecstasy’) abuse [letter]. Lancet 1991; 338: 1335

    Article  PubMed  CAS  Google Scholar 

  79. Wodarz N, Boning J. ‘Ecstasy’ induziertes psychotisches Depersonalisationssyndrom. Nervenarzt 1993; 64: 478–80

    PubMed  CAS  Google Scholar 

  80. McCann UD, Ricaurte GA. Lasting neuropsychiatric sequelae of (±) methylenedioxymethamphetamine (‘ecstasy’) in recreational users. J Clin Psychopharmacol 1991; 11: 302–5

    Article  PubMed  CAS  Google Scholar 

  81. Benazzi F, Mazzoli M. Psychiatric illness associated with ‘ecstasy’ [letter]. Lancet 1991; 338: 1520

    Article  PubMed  CAS  Google Scholar 

  82. O’Callahan J, Miller D. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 1994; 270(2): 741–51

    Google Scholar 

  83. Miller DB, O’Callaghan JP. Environment-, drug-, and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 1994; 270(2): 752–60

    PubMed  CAS  Google Scholar 

  84. Ricaurte GA, McCann UD. Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. Ann NY Acad Sci 1992; 648: 371–82

    Article  PubMed  CAS  Google Scholar 

  85. Ricaurte GA, Finnegan KT, Irwin I, et al. Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: preliminary observations. Ann NY Acad Sci 1990; 600: 699–710

    Article  PubMed  CAS  Google Scholar 

  86. Peroutka SJ, Pascoe N, Faull KF. Monoamine metabolites in the CSF of recreational users of 3,4-methylenedioxymethamphetamine (MDMA; ‘Ecstasy’). Res Comm Substance Abuse 1987; 8: 125–38

    Google Scholar 

  87. Ricaurte GA, Delanney LE, Wiener SG, et al. 5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-human primates. Brain Res 1988; 474: 359–63

    Article  PubMed  CAS  Google Scholar 

  88. Allen RP, McCann, UD, Ricaurte GA. Persistent effects of (+) 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) on human sleep. Sleep 1993; 16(6): 560–4

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

McCann, U.D., Slate, S.O. & Ricaurte, G.A. Adverse Reactions with 3,4-Methylenedioxymethamphetamine (MDMA; ‘Ecstasy’). Drug-Safety 15, 107–115 (1996). https://doi.org/10.2165/00002018-199615020-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199615020-00003

Keywords

Navigation